News Releases

2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
1
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
2
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
3
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
4
2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
5
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
6
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
7
2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
8
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
9
2020-03/25
United BioPharma Received Approval from China NMPA for a Phase 1 Trial with UB-221 in Healthy Volunteers
1
2020-03/24
United BioPharma Received Approval from China NMPA for a Phase 2 Trial to Evaluate the Reduction Effect of UB-421 mAb on Latent HIV Reservoirs in ART-stabilized HIV Patients
2
2020-03/19
San Miguel County orders residents to shelter in place before countywide coronavirus testing
3
2020-03/19
UBI 集團科研能量將攻堅新冠肺炎病毒帶來的人類大災難
4
2019-11/26
United BioPharma Signs clinical trial agreement with NIH/NIAID for sponsorship of a multi-drug resistant HIV trial with UB-421
5
2019-11/08
United BioPharma Receives US FDA Approval for UB-221 Phase 1 IND for Chronic Spontaneous Urticaria
6
2019-10/07
PharmaBoardRoom interview of Dr. Chang Yi Wang, Chairperson and Chief Scientific Officer of United Biopharma (UBP)
7
2019-09/02
United BioPharma successfully completes Taiwan FDA GMP inspection for its 2000L commercial scale manufacturing facility
8
2019-05/14
United BioPharma Receives China NMPA Approval for UB-421 Phase 3 ART-Substitution Trial in HIV-infected Patients
9
Filed IND for UB-421 phase III clinical trial (HAART substitution) to TFDA 2017-01/15
Received certificate of occupancy for UBP’s eight-story (7000 sq Meter) headquarter building based in Huko, Hsinchu county designed for administrative, R&D and large scale protein drug manufacturing activities 2016-12/15
Filed IND for UB-921 (Anti-HER2 monoclonal antibody) phase I clinical trial to TFDA 2016-12/15
UBP entered into a licensing agreement with UBI US Holdings LLC and UBI IP Holdings, the subsidiary of United Biomedical, Inc (UBI) for exclusive US and ROW (ex-Asia) rights for development and commercialization of UB-421 2016-08/15
UB-421 for HIV treatment won the 12th National Innovation Prize given by Taiwan Biotechnology Strategic Planning Association 2015-12/15
IND submission of a phase I clinical trial for UB-621, an Anti-HSV-gD antibody, was approved by Taiwan Food and Drug Administration (TFDA) 2015-11/15
United BioPharma received approval for UB-421 Phase II clinical trial for HAART substitution treatment in treatment stabilized HIV patients from Taiwan Food and Drug Administration (TFDA) 2015-06/15
Filed an IND submission of a phase II clinical trial for HAART substitution therapy in treatment stabilized HIV patients with Taiwan Food and Drug Administration (TFDA) 2015-02/15
UB-421 product received Gold Medal award for 2014 Pharmaceutical Technology Research and Development jointly given by Ministry of Economic Affairs and Minitry of Health, Taiwan 2014-12/15
Filed an IND submission of a phase I clinical trial for UB-621, an anti-HSV-gD antibody, with Taiwan Food and Drug Administration (TFDA) 2014-12/15